Tafluprost
From Infogalactic: the planetary knowledge core
Systematic (IUPAC) name | |
---|---|
isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl}hept-5-enoate
|
|
Clinical data | |
Trade names | Saflutan, Taflotan, Tapros, Zioptan |
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Legal status |
|
Routes of administration |
Topical (eye drops) |
Identifiers | |
CAS Number | 209860-87-7 |
ATC code | S01EE05 (WHO) |
PubChem | CID: 6433101 |
ChemSpider | 8044182 |
UNII | 1O6WQ6T7G3 |
ChEBI | CHEBI:66899 |
ChEMBL | CHEMBL1963683 |
Chemical data | |
Formula | C25H34F2O5 |
Molecular mass | 452.531266 g/mol |
|
|
|
Tafluprost (trade names Taflotan, marketed by Santen Pharmaceutical and Zioptan, by Merck (U.S.)) is a prostaglandin analogue used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure by increasing the outflow of aqueous fluid from the eyes.[1][2]
Taflotan contains 15 µg/ml Tafluprost. Taflotan sine is a preservative-free, single-dose formulation containing 0.3 ml per dose.[3]
References
- ↑ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2008/2009
- ↑ Santen Home Page
- ↑ Gelbe Liste (in German)
<templatestyles src="Asbox/styles.css"></templatestyles>
4. Sethi HS, Dhawan M, Naik MP, Gupta VS. Prostaglandin analogs in glaucoma. Astrocyte 2015;2:126-32.